Compare Panacea Biotech with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs IPCA LABS - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH IPCA LABS PANACEA BIOTECH/
IPCA LABS
 
P/E (TTM) x 11.4 21.0 54.4% View Chart
P/BV x 2.7 4.1 67.4% View Chart
Dividend Yield % 0.0 0.1 -  

Financials

 PANACEA BIOTECH   IPCA LABS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
IPCA LABS
Mar-18
PANACEA BIOTECH/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs364695 52.3%   
Low Rs129400 32.3%   
Sales per share (Unadj.) Rs96.8260.2 37.2%  
Earnings per share (Unadj.) Rs-12.419.0 -65.4%  
Cash flow per share (Unadj.) Rs-2.933.1 -8.6%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs50.4213.0 23.7%  
Shares outstanding (eoy) m61.25126.20 48.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.52.1 121.0%   
Avg P/E ratio x-19.928.9 -68.8%  
P/CF ratio (eoy) x-86.416.6 -521.7%  
Price / Book Value ratio x4.92.6 190.3%  
Dividend payout %05.3 0.0%   
Avg Mkt Cap Rs m15,10169,120 21.8%   
No. of employees `0002.513.3 18.6%   
Total wages/salary Rs m1,5167,359 20.6%   
Avg. sales/employee Rs Th2,401.92,477.4 97.0%   
Avg. wages/employee Rs Th614.2555.2 110.6%   
Avg. net profit/employee Rs Th-307.9180.6 -170.5%   
INCOME DATA
Net Sales Rs m5,92832,836 18.1%  
Other income Rs m82418 19.7%   
Total revenues Rs m6,01033,254 18.1%   
Gross profit Rs m8454,505 18.8%  
Depreciation Rs m5851,777 32.9%   
Interest Rs m1,006240 418.7%   
Profit before tax Rs m-6642,905 -22.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m99511 19.3%   
Profit after tax Rs m-7602,394 -31.7%  
Gross profit margin %14.313.7 103.9%  
Effective tax rate %-14.917.6 -84.5%   
Net profit margin %-12.87.3 -175.8%  
BALANCE SHEET DATA
Current assets Rs m5,60319,455 28.8%   
Current liabilities Rs m6,91010,076 68.6%   
Net working cap to sales %-22.028.6 -77.2%  
Current ratio x0.81.9 42.0%  
Inventory Days Days20698 210.2%  
Debtors Days Days8467 125.1%  
Net fixed assets Rs m9,94120,260 49.1%   
Share capital Rs m61252 24.3%   
"Free" reserves Rs m3,02626,633 11.4%   
Net worth Rs m3,08726,886 11.5%   
Long term debt Rs m5,7072,340 243.9%   
Total assets Rs m16,07641,173 39.0%  
Interest coverage x0.313.1 2.6%   
Debt to equity ratio x1.80.1 2,124.1%  
Sales to assets ratio x0.40.8 46.2%   
Return on assets %1.56.4 23.9%  
Return on equity %-24.68.9 -276.5%  
Return on capital %3.910.8 36.4%  
Exports to sales %24.047.6 50.4%   
Imports to sales %17.514.9 117.9%   
Exports (fob) Rs m1,42415,642 9.1%   
Imports (cif) Rs m1,0404,884 21.3%   
Fx inflow Rs m1,60015,642 10.2%   
Fx outflow Rs m1,1314,884 23.2%   
Net fx Rs m46910,759 4.4%   
CASH FLOW
From Operations Rs m1,1803,411 34.6%  
From Investments Rs m553-1,354 -40.8%  
From Financial Activity Rs m-1,644-1,304 126.0%  
Net Cashflow Rs m90753 11.9%  

Share Holding

Indian Promoters % 74.5 45.9 162.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 11.4 5.3%  
FIIs % 1.3 25.3 5.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 17.4 135.6%  
Shareholders   10,259 36,892 27.8%  
Pledged promoter(s) holding % 35.1 2.1 1,638.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALKEM LABORATORIES  ELDER PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Oct 14, 2019 01:39 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS